Intellectual Property India Publishes Patent Application for 'Treatment Of Acute Myeloid Leukemia With Olutasidenib, Venetoclax And A Hypomethylating Agent' Filed by Rigel Pharmaceuticals, Inc.

MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202617013246 A) filed by Rigel Pharmaceuticals, Inc., San Francisco, on Feb. 6, for 'treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent.'

Inventor(s) include Chao, Mwe Mwe; and Dinardo, Courtney.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "Provided are methods of treating a subject having a hematologic malignancy or pre-malignancy that involve administering an effective amount of olutasidenib, venetoclax, and a hypomethylating agent. In some cases, the patient has an IDH1 mutation."

The patent ap...